One hundred women undergoing elective lower uterine segment Caesarean section iinrfw extradural anaesthesia received either 0.5% or 0.75% plain bupivacaine or 1.5% etidocaine with adrenaline 1:200 000 by random allocation. The time taken to establish satisfactory blockade for surgery was significantly shorter in the etidocaine group compared with either of the bupivacaine groups (P< 0.001). There were no significant differences in the durations of either nnalg<-«ia or motor blockade in the three groups. The efficacy of the sensory blockade, measured by the incidence of discomfort during the surgical procedure and the requirements for supplementary nnnigi-nia or general anaesthesia, was greater in the bupivacaine groups compared with the etidocaine group. Measurement of plasma bupivacaine concentrations in 34 of the patients revealed significantly increased umbilical venous concentrations at the time of birth in those who received 0.75% bupivacaine (P < 0.05). There was no advantage in the use of bupivacaine in concentrations exceeding 0.5%. Etidocaine 1.5% may be of some value in situations where minimal delay in establishing adequate extradural blockade for surgery is desirable, but in view of its comparatively poor analgesic effects, routine use is not recommended.
The use of lumbar extradural anaesthesia for lower uterine segment Caesarean section has become commonplace in the United Kingdom. The introduction of more concentrated solutions of bupivacaine and etidocaine has been reported to provide a more rapid onset of sensory and motor blockade with better analgesia during labour (Scott et al., 1980) . The purpose of the present study was to establish whether or not such advantages would be significant in operative obstetric practice and, if so, whether these would be offset by an increase in the incidence of associated complications, or systemic effects associated with the administration of larger total doses of local anaesthetic solution.
PATIENTS AND METHODS
The study was carried out in two maternity hospitals in Glasgow-The Queen Mother's Hospital (QMH) and Rutherglen Maternity Hospital (RMH). All patients were undergoing elective lower uterine segment Caesarean section under extradural anaesthesia. At QMH, 60 patients were allocated randomly to three groups of 20 and received 0.5% or 0.75% plain bupivacaine, or 1.5% etidocaine with adrenaline 1:200000. At RMH, 40 patients were allocated randomly to two groups (20 each) and received either 0.5% or 0.75% bupivacaine plain. Overall, 40 patients received 0.5% bupivacaine, 40 received 0.75% bupivacaine, and 20 received 1.5% etidocaine.
A standard technique was used throughout the study, utilizing a "two-stage" top-up procedure (Thorburn and Moir, 1980) . The initial "sitting up" dose of 8-10 ml of local anaesthetic solution was followed, after a period of 10 min, by a second dose administered with the patient in the horizontal wedged position. The second dose was calculated according to the number of spinal segments remaining unblocked up to T6 level. Patients in the 0.5% bupivacaine group received a further 1.5 ml per segment unblocked, and patients in the other two groups (0.75% bupivacaine and 1.5% etidocaine) received 1 ml per segment unblocked. Any further top-ups required to achieve acceptable blockade for surgery were given with the patient tilted 10° headdown. Once satisfactory sensory and motor blockade had been established, the surgical procedure was commenced. The time taken to achieve blockade (timed from the administration of the first dose of local anaesthetic) was recorded. The quality and completeness of the motor and sensory blockade were recorded during surgery. The efficacy of sen-sory blockade was judged by the presence or absence of pain or discomfort and the need for systemic analgesia or general anaesthesia.
Any evidence of nausea, vomiting, hypotension (defined as a decrease in systolic arterial pressure to less than 90 mm Hg), and shivering was noted.
Plasma bupivacaine concentrations were measured in the patients studied at RMH. Two maternal samples were taken, the first 30 min after the initial dose of bupivacaine, and the second at the time of delivery. A fetal sample (umbilical venous) was taken at the time of delivery.
The condition of the neonate at birth was assessed by Apgar scoring at 1 and 5 min, and by the time to the establishment of sustained respiration (TSR).
After surgery, the durations of analgesia and motor blockade were assessed by timing the intervals between the initial dose of local anaesthetic solution and the administration of postoperative analgesic drugs, and the ability of the patient to perform a straight leg-raising manoeuvre, respectively. On the following day, each patient was visited, asked to comment on her experience and to state whether or not she would undergo a similar procedure under extradural analgesia in the future. At the same time, any late complications-with particular reference to bladder function-were recorded.
Statistics
Results were analysed using the following tests of statistical significance where appropriate:
Analysis of variance by calculation ofF ratio: comparison of mean volumes of local anaesthetic administered and the times of onset and duration of blockade.
Student's t test: comparison of mean total doses of local anaesthetic administered and the fetal and maternal plasma concentrations between the two groups receiving bupivacaine.
Chi-squareaXx 2 ) test with Yates' correction factor for small samples where applicable: comparison of the assessment of the efficacy of sensory blockade and the incidence of complications.
Correlation coefficient and its significance (t test): assessment of the relationship between dose and plasma concentrations of bupivacaine.
Bupivacaine analysis
Plasma samples were analysed for bupivacaine using a modification of the method of Zylber-Katz, Granit, and Levy (1978) . A Pye Unicam 204 series gas chromatograph fitted with a flame ionization detector was used. Extracted samples were separated on a2m x 2 mm i.d. glass column packed with 3% SP2250 on Supelcoport (100/120 mesh). Carrier gas was oxygen-free nitrogen at a flow rate of 20 ml min~' and the column oven was maintained at 250 °C with the injection port and detector set at 275 °C and 300 °C, respectively.
RESULTS
Details of the mean ages, weights and heights of the patients studied are shown in table I. There were no significant differences between the three groups.
Volume and dose of local anaesthetic administered (table II)
The mean volumes differed significantly between the three groups (P< 0.01), with the etidocaine and 0.75% bupivacaine groups requiring, on average, 35% and 15% smaller volumes, respectively, when compared with the 0.5% bupivacaine group. Despite the smaller volumes administered to the 0.75% bupivacaine group, a significantly larger total dose of local anaesthetic was administered when compared with the 0.5% bupivacaine group (P < 0.001). Onset, and duration of blockade (table III) The mean times to establish satisfactory blockade differed significantly between the groups (P< 0.01), with the etidocaine group (mean 21 min) having a significantly shorter duration of onset compared with both bupivacaine groups (P< 0.001). There was no significant difference between the mean onset times of 0.5% bupivacaine (42 min) and 0.75% bupivacaine (46 min). No significant differences were established between the duration of analgesia or motor blockade among the groups.
Intensity of motor blockade
In the etidocaine group, all patients in whom satisfactory blockade for surgery had been established developed complete motor paralysis. Seventeen patients in the 0.75% bupivacaine group (45%) and 16 in the 0.5% bupivacaine group (40%) retained toe movements throughout the procedure. Four patients in the etidocaine group found the intensity of the motor blockade unacceptable, compared with two patients in the 0.5% bupivacaine group and none in the 0.75% bupivacaine group.
Complications (table IV)
The incidence of hypotension was similar in all three groups. Of the 10 patients in the 0.5% bupivacaine group in whom systolic arterial pressure decreased to less than 90mmHg, seven received ephedrine i.v., and in three the volume of fluid administered was increased. In the 0.75% bupivacaine group, nine patients required ephedrine and two increased fluid i.v.; in the etidocaine group, four patients required ephedrine and one increased fluids i.v. only. Details of the incidence of other complications (nausea and vomiting, shivering, and urinary retention) are shown in table IV. The incidence of shivering was significantly greater in the 0.5% bupivacaine group compared with the 0.75% bupivacaine group (P<0.05). There was no correlation between shivering and the total dose of local anaesthetic drug administered. There were no significant differences in the incidences of nausea and vomiting or urinary retention between the groups.
Efficacy of sensory blockade (table V)
The efficacy of sensory blockade was assessed by placing each patient into one of four categories. Patients in category A experienced no discomfort at all during the procedure. Those in category B complained of mild discomfort which did not require systemic analgesia. The pain experienced by the patients in category C required extra inhalation or i.v. analgesia and, in category D, was severe enough to warrant the administration of general anaesthesia. Three patients were excluded from this assessment (two from the etidocaine group and one from the 0.75% bupivacaine group) because general anaesthesia was commenced before surgical incision because of failure to achieve an adequate degree of sensory blockade (defined by loss of pinprick sensation). The efficacy of the sensory block was significantly better in the 0.5% bupivacaine group compared with the etidocaine group (P<0.02). There was no significant difference between the bupivacaine groups. Patient assessment of willingness to undergo a future similar procedure under extradural blockade (table VI) was similar in all three groups.
Condition of the neonate (table VII)
The condition of all the neonates was satisfactory and no differences could be defined between the groups. With the exception of one neonate (premature-33 weeks gestation), all had Apgar scores of 9 or 10 at 5 min and only four had a TSR in excess of 60 s.
Plasma bupivacaine concentrations (table VIII)
Sixteen patients in the 0.5% bupivacaine group and 18 in theO. 75% bupivacaine group had maternal and fetal plasma concentrations assayed. There were no significant differences in the maternal plasma concentrations either at 30 min from the initial dose of bupivacaine or at the time of delivery, between the two groups. Despite this, five patients in the 0.75% group had concentrations greater than 1.6ngml"' at 30min (maximum 2.18 ngml" 1 ) com- pared with none in the 0.5% group (maximum 1.52 fig ml" 1 ). Mean fetal plasma concentrations (umbilical venous at delivery) were significantly greater in the 0.75% group (P<0.05). There were no significant differences in the feto:maternal plasma ratios of bupivacaine between the groups. There was a significant correlation between the sum of the two initial doses of bupivacaine ("sitting up" and "horizontal wedged") and the plasma concentrations at 30min from the first dose (P<0.01), ( fig.  1 ). 
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DISCUSSION
Previous reports have described the advantages and disadvantages of bupivacaine and etidocaine, in various concentrationSj for extradural blockade in lower abdominal surgery (Lund, Cwik and Pagdanganan, 1973; Bridenbaugh et al., 1973; Moore etal., 1974; Bridenbaugh ct al., 1976; Scott et al., 1980) , surgical induction of labour (Phillips, 1975) , and pain relief in labour (Engberg, Holmdahl and Edstrom, 1974; Moore et al., 1975; Littlewood et al., 1977) . There were two main observations of interest. First, the comparative rapidity of the onset of both sensory and motor blockade obtained with etidocaine (1% and 1.5%) and, second, the greater frequency of adequate analgesia with longer duration of sensory and motor blockade during surgical procedures when both drugs were used in higher concentrations (0.75% bupivacaine and 1.5% etidocaine). The results from our study support clearly the previous findings concerning the rapid onset of block with etidocaine. We were able to decrease the mean time taken to establish blockade adequate for surgery by 50% using the "two-stage" top-up procedure described. We could not, however, demonstrate any significant difference between 0.5% and 0.75% bupivacaine in the time of onset of blockade. Likewise, we found no differences in the duration of analgesia or motor blockade between the three groups. In 65% of patients who received etidocaine, motor blockade of the legs (lumbo-sacral roots) outlasted the duration of analgesia of the lower abdomen (assessed by the onset of wound pain). The corresponding figure for those patients who received bupivacaine (0.5% or 0.75%) was 40%. However, such observations must be measured against their clinical significance, and only six patients (four in the etidocaine group and two in the 0.5% bupivacaine group) expressed concern about the intensity or duration of motor blockade and, of these, four were quite happy to have the procedure repeated under extradural analgesia in the future.
The advantage of the comparatively rapid onset of blockade obtained with etidocaine was, however, tempered by the relatively poor degree of analgesia, which was found to be significantly less than that provided by 0.5% bupivacaine. The assessment of the efficacy of sensory blockade did not take into account patients in whom satisfactory blockade could not be achieved and, as a consequence, received general anaesthesia before the surgical incision (two patients in the etidocaine group, and one in the 0.75% bupivacaine group). In addition, patients who received sedation (e.g. diazepam i.v.) purely for anxiety were not categorized as having experienced pain. Overall, therefore, 20% of the patients who received etidocaine subsequently required general anaesthesia, and only 33% experienced the procedure without discomfort, compared with just over 60% of patients who received bupivacaine. Our findings suggest that, in terms of improving the efficacy of sensory blockade, there is no real advantage in using the higher concentration of bupivacaine, and that the necessity to administer additional analgesia or general anaesthesia to over 50% of patients receiving 1.5% etidocaine casts serious doubts upon its use for extradural anaesthesia in obstetrics. However, the assessment of the efficacy of sensory blockade did not mirror exactly the patient assessment in terms of whether or not she would be willing to undergo a similar procedure again under extradural analgesia. There were no significant differences in this response between the three groups.
The incidence of hypotension was constant between the three groups. A similar proportion of patients in each group were managed by increasing i.v. fluids or by ephedrine. In the etidocaine group, to prevent hypotension as a result of the rapid onset of autonomic blockade, the procedure of fluid preloading was modified slightly. The normal practice with the initial 1-litre pre-load of lactated Ringer's solution was to infuse 500 ml before the administration of any local anaesthetic to the extradural space, and then follow this with a further 500 ml during establishment of the blockade (i.e. over 20-30 min). In the etidocaine group, it was considered prudent to infuse the entire 1 litre before the initial dose of local anaesthetic. The overall incidence of hypotension in this series of patients is fairly high (26%) and may indicate the need to use larger volumes (e.g. 1.5-2.0litre) of fluid pre-load, as suggested by Lewis, Thomas and Wilkes (1983) , while establishirtgjng extradural blockade.
In the United Kingdom, the recommended maximum safe dose of bupivacaine (with or without adrenaline) within any 4-h period remains at 2mgkg~1. Such restrictions have been considered too stringent (Moore et al., 1977) , and in a series of 11080 patients who received bupivacaine, in doses ranging from 25 to 600 mg (Moore etal., 1978) , only 15 patients experienced systemic toxicity, which, in 13 was as a result of inadvertent intravascular injection. It is, perhaps, pertinent to note that 84% of these blocks were obtained with solutions containing adrenaline. Reynolds and Taylor (1971) suggest that this may decrease the occurrence of maternal toxicity when large doses of bupivacaine are administered during continuous extradural analgesia in labour. In our series, we found that, in 50% of patients given 0.75% bupivacaine, the total dose exceeded 2 mg kg" 1 , compared with only 20% of the patients who received 0.5% bupivacaine. Despite this, we observed no clinical signs of toxicity in any patient. We agree with Moore and his colleagues (1978) that shivering, which occurred in 13 of our patients, is unlikely to be a manifestation of systemic toxicity. Nine of these patients received bupivacaine, and five had plasma concentrations estimated. The maximum concentration recorded in this group was 0.96 /xg ml" 1 . It was reassuring that we could not establish any significant difference in the maternal venous plasma bupivacaine concentrations (either at 30 min or at deb"very) between the two groups, despite the significantly larger mean total dose administered to the 0.75% group. In some patients (six in the 0.75% group and eight in the 0.5% group) the maternal plasma concentrations at delivery exceeded the 30-min values. This reflected the necessity, in some patients, to administer additional top-ups after the second dose to achieve adequate blockade. Although the umbilical venous plasma concentrations were significantly higher in the 0.75% bupivacaine group, no difference was established in the neonatal assessment at birth between the groups. Two previous studies (Magno, Berlin and Karlsson, 1976; McGuinness, Merkow and Kennedy, 1978) when compared with our study show that, despite a considerable variation in the dose of 0.75% bupivacaine plain administered for extradural Caesarean section, the umbilical venous concentrations of bupivacaine at delivery remained remarkably constant. What does remain in some doubt is the relationship between maternal plasma concentrations and systemic toxicity. Reynolds (1971) predicted that mild toxic symptoms will not occur with a venous plasma concentration of less than 1.6 ng ml" 1 , which implies that, above this value, there may be increased likelihood of systemic toxicity. Concentrations at which signs of severe toxicity may appear have been estimated to be in excess of 4ngml~I (Jorfeldt, Lofstrorn and Pernow, 1968; Mather, Lord and Thomas, 1971) . It is not entirely clear how significant a risk is imposed upon a patient who achieves plasma concentrations between 1.6 and 4ngml"'.
Although, in our series, we found no significant difference in the maternal bupivacaine concentrations between the groups, all patients in the 0.5% group had concentrations at 30 min and delivery of less than 1.6fxgml -1 . Five of the 18 patients in the 0.75% group had concentrations in excess of this value at 30min (maximum 2.18 ngml" 1 )-We feel that it would be prudent to select a maximum dose of bupivacaine for each patient which should not be exceeded.
We conclude that there is no real advantage to the use of 0.75% bupivacaine in extradural anaesthesia for Caesarean section using the technique that we have described. Increasing the concentration of bupivacaine did not improve the efficacy of sensory blockade, or increase the degree or duration of motor blockade. Thus, there is little justification for the administration of larger total doses of bupivacaine. Etidocaine 1.5% appears to have only the one clear advantage of a rapid onset of action and this may be of some value in certain situations. However, its tendency to precipitate when mixed with cerebrospinal fluid (Moore, 1981) precludes consideration for routine use in this setting. Buprvacacain und l,5%igem Etidocain
